Kinnate Biopharma's market cap is currently ―. The company's EPS TTM is $-2.424; its P/E ratio is -1.09; Kinnate Biopharma is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-0.29. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	$ -17.09M	$ -30.73M	$ -31.92M	$ -34.65M	$ -32.73M
EBITDA	$ -18.08M	-	$ -32.86M	$ -35.19M	$ -32.84M
Net Income Common Stockholders	$ -17.06M	$ -30.73M	$ -31.92M	$ -32.94M	$ -31.61M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 154.03M	$ 167.58M	$ 184.70M	$ 200.98M	$ 227.20M
Total Assets	$ 173.60M	$ 190.71M	$ 216.18M	$ 243.88M	$ 278.83M
Total Debt	$ 3.17M	$ 3.38M	$ 3.70M	$ 3.95M	$ 4.18M
Net Debt	$ -150.86M	$ -164.19M	$ -181.00M	$ -197.03M	$ -223.02M
Total Liabilities	$ 14.28M	$ 18.29M	$ 18.52M	$ 21.12M	$ 20.36M
Stockholders Equity	$ 159.33M	$ 172.42M	$ 197.64M	$ 222.76M	$ 223.47M
Cash Flow	-
Free Cash Flow	$ -17.36M	-	$ -29.41M	$ -27.73M	$ -23.84M
Operating Cash Flow	$ -17.36M	$ -25.54M	$ -29.42M	$ -27.72M	$ -23.75M
Investing Cash Flow	$ 22.70M	$ 42.63M	$ -10.88M	$ 55.42M	$ 17.57M
Financing Cash Flow	-	$ 57.00K	$ 1.25M	$ -9.12M	$ 193.00K

Currency in USD

Kinnate Biopharma Earnings and Revenue History

Income Statement >

Kinnate Biopharma Debt to Assets

Balance Sheet >

Kinnate Biopharma Cash Flow

Cash Flow >

Kinnate Biopharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing